Keynote Lecture: Innovation in BTK Intervention: Clinical and Technical Lessons Learned From Recent DCB and DES Trials
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - Medtronic; Boston Scientific Corporation
- Consultant Fee/Honoraria/Speaker's Bureau - Medtronic; Boston Scientific Corporation; Phillips
- Equity/Stock(s)/Options - Syntervention; Tissue Gen; Transit Medical; Primacea; Cagent; R3
- Royalty/Intellectual Property Rights - Innovation Vascular Partners, Consulting LLC (founder)